Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824161 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
A Phase 2 study, sponsored by Taiho Pharmaceutical Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00824161: Clinical Trial Phase 2 study, sponsored by Taiho Pharmaceutical Co..
NCT00824161 is a Phase 2 study that was terminated before completion, run by Taiho Pharmaceutical Co.. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00824161, a Phase 2 study, was terminated before completion, sponsored by Taiho Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
Primary Outcome
The primary endpoint was percentage of progression free survival as defined by the percentage of patients without progressive disease(PD)or death, whichever came first, at 3 months of therapy.
Interventions
- DRUG TAS-109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Why NCT00824161 stopped before completion
NCT00824161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which TAS-109 is the first listed.
NCT00824161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00824161 about?
NCT00824161 is a clinical study titled "Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer". The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
What is the current status of trial NCT00824161?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00824161?
The interventions under investigation include: TAS-109 (DRUG).
Who is sponsoring clinical trial NCT00824161?
This trial is sponsored by Taiho Pharmaceutical Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00824161's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia